We are live on ! Find out more
RCKT icon

Rocket Pharmaceuticals
RCKT

236 hedge funds and large institutions have $722M invested in Rocket Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 112 increasing their positions, 41 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

173% more repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 41

172% more call options, than puts

Call options by funds: $3.92M | Put options by funds: $1.44M

37% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 35

5% more funds holding

Funds holding: 225 → 236 (+11)

2% less ownership

Funds ownership: 103.11% → 101.11% (-2%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

48% less capital invested

Capital invested by funds: $1.38B → $722M (-$655M)

Holders
236
Holders Change
+11
Holders Change %
+4.89%
% of All Funds
3.16%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
48
Increased
112
Reduced
41
Closed
35
Calls
$3.92M
Puts
$1.44M
Net Calls
+$2.48M
Net Calls Change
+$2.67M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$14.4M
2
BBA
Baker Bros. Advisors
New York
+$9.88M
3
SCM
Suvretta Capital Management
New York
+$9.24M
4
NCM
Nantahala Capital Management
Connecticut
+$6.22M
5
MB
MPM BioImpact
Massachusetts
+$5.91M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$25.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$19.7M
3
BCM
Boxer Capital Management
California
-$18.4M
4
ACA
Avoro Capital Advisors
New York
-$15.1M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$13.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$4.98M +$4.05M +410,238 +122%
Northern Trust
27
Northern Trust
Illinois
$4.67M +$367K +37,149 +6%
Charles Schwab
28
Charles Schwab
California
$4.51M +$192K +19,391 +3%
WP
29
Woodline Partners
California
$4.35M +$4.39K +444 +0.1%
UBS Group
30
UBS Group
Switzerland
$4.32M +$769K +77,867 +14%
NCM
31
Nantahala Capital Management
Connecticut
$4.2M +$6.22M +629,749 New
JP Morgan Chase
32
JP Morgan Chase
New York
$4.07M +$934K +94,561 +18%
SL
33
Siren LLC
Connecticut
$3.94M -$86.3K -8,737 -1%
Dimensional Fund Advisors
34
Dimensional Fund Advisors
Texas
$3.85M -$1.81M -183,453 -24%
Schroder Investment Management Group
35
Schroder Investment Management Group
United Kingdom
$3.14M – – –
MA
36
MYDA Advisors
New York
$3.07M +$4.55M +460,381 New
Marshall Wace
37
Marshall Wace
United Kingdom
$2.93M -$179K -18,145 -4%
PFM
38
Privium Fund Management
Netherlands
$2.89M +$347K +35,110 +9%
VC
39
Voss Capital
Texas
$2.88M +$104K +10,540 +2%
Bank of America
40
Bank of America
North Carolina
$2.81M +$1.95M +197,176 +88%
Federated Hermes
41
Federated Hermes
Pennsylvania
$2.76M +$4.1M +414,497 New
Invesco
42
Invesco
Georgia
$2.67M +$426K +43,129 +12%
MCM
43
M28 Capital Management
Connecticut
$2.57M – – –
Balyasny Asset Management
44
Balyasny Asset Management
Illinois
$2.35M +$3.49M +352,957 New
Renaissance Technologies
45
Renaissance Technologies
New York
$2.26M +$1.19M +119,955 +55%
SA
46
Sovran Advisors
California
$2.05M +$1.7M +172,324 +114%
Walleye Capital
47
Walleye Capital
New York
$1.91M +$661K +66,946 +30%
SF
48
Synovus Financial
Georgia
$1.86M +$1.13M +114,557 +70%
SFM
49
Sphera Funds Management
Israel
$1.81M – – –
JF
50
Jump Financial
Illinois
$1.69M +$2.51M +253,723 New
1
2
3 4 5

RCKT Hedge Fund Activity: Q1 2025 in Review

236 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2025, worth a combined $722M — down 48% from $1.38B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new RCKT positions and 35 closed out — a net gain of 13 holders — while 112 added to existing stakes and 41 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $14.4M. The largest seller was Citadel Advisors, cutting an estimated $25.8M.

  • 236 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2025, up from 225 in Q4 2024.
  • Funds reported $722M of Rocket Pharmaceuticals stock for Q1 2025, down 48% quarter-over-quarter.
  • 48 funds opened new Rocket Pharmaceuticals positions in Q1 2025 and 35 closed out, a net change of +13 holders.
  • The largest Rocket Pharmaceuticals buyer in Q1 2025 was Morgan Stanley, an estimated $14.4M added.
  • The largest Rocket Pharmaceuticals seller in Q1 2025 was Citadel Advisors, an estimated $25.8M sold.

Based on aggregated 13F filings for Q1 2025.